Trial wins Prize

Deltex Medical Group PLC
27 May 2005

                             Deltex Medical Group plc

 Clinical trial using non-invasive cardiac function and blood flow monitor wins
               first prize at two international clinical meetings

27 May 2005: Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
AIM listed haemodynamic monitoring company, today announces that a clinical
trial that used the Company's wholly non-invasive cardiac function and blood
flow monitor, the SupraQ(TM), has been awarded first prize for clinical research
at two separate international clinical meetings.

Doctors at the Royal Free Hospital in London have for some time been using the
SupraQ to monitor haemodynamic changes in patients undergoing caesarean section.
In this trial the monitor was used to determine the relative effectiveness of
two drugs in maintaining blood pressure during the procedure.

The results were presented and awarded first prize at the Society of Obstetric
Anesthesia and Perinatology meeting held in Palm Desert, California, USA and at
the Obstetric Anaesthetists' Association meeting held in London in May 2005.

Dr Roshan Fernando, who led the research team, commented: 'The SupraQ has proved
an invaluable tool in looking after mothers with medical problems during
pregnancy and delivery. It has also been used in mothers during awake caesarean
section under spinal anaesthesia to evaluate blood pressure control, aiming to
prevent very common side effects from the spinal anaesthetic - blood pressure
falls, nausea and vomiting - using new drug infusion techniques. These
techniques have also proven to be of benefit both to the mother and the baby.'

Andy Hill, Deltex Medical's Chief Executive, commented:  'The SupraQ allows
doctors to monitor heart function in awake patients, safely and quickly and
therefore intervene rapidly to deal with a problem as soon as it is detected. We
believe that the ease of use and non-invasive nature of the SupraQ will make it
the haemodynamic monitoring solution of choice in awake patients and those
undergoing surgery without general anaesthesia.'


For further information, please contact:-

Deltex Medical Group plc                                       01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
David Yates                                                    0207 831 3113
Lucy Briggs

Royal Free Hospital
Dr Roshan Fernando                                 [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.



                      This information is provided by RNS
            The company news service from the London Stock Exchange